Essential thrombocytosis pathophysiology

Essential thrombocytosis Microchapters
Home
Patient Information
Overview
Historical Perspective
Classification
Pathophysiology
Epidemiology and Demographics
Risk Factors
Screening
Causes
Differentiating Essential thrombocytosis from other Diseases
Natural History, Complications and Prognosis
Diagnosis
Diagnostic Criteria
History and Symptoms
Physical Examination
Laboratory Findings
Electrocardiogram
Chest X Ray
CT
MRI
Echocardiography or Ultrasound
Other Imaging Findings
Other Diagnostic Studies
Treatment
Medical Therapy
Surgery
Primary Prevention
Secondary Prevention
Cost-Effectiveness of Therapy
Future or Investigational Therapies
Essential thrombocytosis pathophysiology On the Web
Most recent articles
Most cited articles
Review articles
CME Programs
Powerpoint slides
Images
American Roentgen Ray Society Images of Essential thrombocytosis pathophysiology All Images X-rays Echo & Ultrasound CT Images MRI
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on Essential thrombocytosis pathophysiology
CDC on Essential thrombocytosis pathophysiology
Essential thrombocytosis pathophysiology in the news
Blogs on Essential thrombocytosis pathophysiology
Directions to Hospitals Treating Essential thrombocytosis
Risk calculators and risk factors for Essential thrombocytosis pathophysiology

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]Associate Editor(s)-in-Chief: Soujanya Thummathati, MBBS [2]

Overview

Essential thrombocytosis arises from hematopoietic stem cells which give rise to megakaryocytes which give rise to platelets (thrombocytes), that are normally involved in blood clotting. Development of essential thrombocytosis is the result of a genetic mutation in the janus kinase 2 (JAK2) gene in 50% of the patients. Other genes that may be involved in the pathogenesis of essential thrombocytosis are CALR, MPL, and THPO genes. On microscopic histopathological analysis, thrombocytosis, bone marrow hyperplasia with hyperlobated megakaryotic nuclei evident of thrombopoiesis are characteristic findings of essential thrombocytosis.

Pathophysiology

• Essential thrombocytosis arises from pluripotent hematopoietic stem cells of megakaryocytic lineage that give rise to platelets.
• Essential thrombocytosis is caused by point mutations in janus kinase 2 (JAK2) gene in 50% of the patients
• Thrombopoietin destruction is also critical to the development of essential thrombocytosis.
  • Thrombopoietin normally regulates the stimulation, production, and proliferation of megakaryocytes.
  • Despite the high platelet count, essential thrombocytosis paradoxically manifests with an increase in free circulating concentration of thrombopoietin as the abnormal platelets have defective thrombopoietin receptors which impair proper binding of thrombopoietin.
• Platelets contain different types of granules: alpha (contain P-selectin, platelet factor 4, transforming growth factor-β1, platelet-derived growth factor, fibronectin, B-thromboglobulin, vWF, fibrinogen, and coagulation factors V and XIII), delta (δ) or dense granules (contain ADP or ATP, calcium, and serotonin), gamma (γ), and lambda (λ) granules.
  • With defective granules in essential thrombocytosis, there is a deficiency in clotting factors like fibrinogen and von Willebrand (vWF), which impairs the process of aggregation.
  • On the other hand, patients with secondary or reactive thrombocytosis have normal platelet activity with no defects in aggregation.

• 

  CFU-Me (pluripotential hemopoietic stem cell or hemocytoblast) to the formation of megakaryocyte.

Genetics

• Essential thrombocytosis is associated with mutations in janus kinase 2 (JAK2) gene in 50% of the patients.
• Janus kinase 2, a non-receptor tyrosine kinase protein belonging to the janus kinase family, helps in signaling pathways involved in hematopoiesis (including thrombopoietin, erythropoietin, granulocyte-colony stimulating factor, Bcl-2, and interleukin-3,5).
  • A point mutation from G to T that results in the substitution of valine for phenylalanine at amino acid 617 of the JAK2 protein first activates the tyrosine kinase in JAK2 and subsequently results in the activation of the JAK-STAT pathway.
  • Activation of the JAK-STAT pathway results in abnormal differentiation and proliferation of the precursor cells, releasing the increased pool of platelets into the circulation.
• Mutations in the calreticulin (CALR) gene has been identified in patients with essential thrombocytosis who lacked JAK2 mutations.
  • The mechanism by which the mutation triggers the disease remains unknown.
• MPL (myeloproliferative leukemia protein) and THPO (thrombopoietin) gene mutations may also result in the activation of JAK-STAT pathway, causing abnormal platelet proliferation.

Microscopic Pathology

• A complete blood count shows marked elevation of platelet count greater than or equal to 600,000/μL of blood and sometimes even higher.
• The platelet shape and size usually remain unchanged, but variations may occur.
• The red cell morphology depends on the presence and severity of bleeding.
• The white cell count remains slightly elevated.
• Bone marrow biopsy is the definitive diagnostic test for essential thrombocytosis. The bone marrow is usually hypercellular, though it can be normocellular. The megakaryocytes are bigger in size and have hyperlobated nuclei which is the characteristic feature of increased thrombopoiesis. Cells are usually stainable with iron, provided the patient had no significant hemorrhagic events. Collagen fibrosis is typically absent.

• 

  This represents a platelet count between 1.5 and 2 million per microliter (normal range is between 0.150 and 0.450 million). The patient had had an elevated count for at least 15 years but is asymptomatic.

• 

  Histopathological image representing a bone marrow aspirate in a patient with essential thrombocythemia. Hematoxylin & eosin stain.

References

Template:WikiDoc Sources